13 August 2018 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting four new medicines.

Niraparib (Zejula) was accepted for use for advanced ovarian cancer. It was considered through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines that treat end of life and very rare conditions. 

Alectinib (Alecensa) was accepted for the treatment of a specific rare type of advanced non-small cell lung cancer. Patients are often diagnosed when the disease is at a late stage and treatment options are limited. Alectinib offers the benefit of an increase in the time to disease progression compared with existing therapy.

Read SMC press release